A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosisAlena Novotná, Zdeněk Ambler, Claudio Gasperini et al.|European Journal of Neurology|2011Cited by 465
Default-mode network dysfunction and cognitive impairment in progressive MSMaria A. Rocca, Massimo Filippi, Martina Absinta et al.|Neurology|2010Cited by 320